Filing Flows › Health Care › Bioadaptives (BDPT)
Bioadaptives (BDPT) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 19, 2026 · Bioadaptives (BDPT) Q2 2026 earnings results →
Q2 2026 Revenue up 55% year over year to $5K
Bioadaptives made $5K in Q2 2026 (+55% Y/Y). Operating margin n/m, net earnings $150K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 19, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $5K in Q2 2026, up 55% year over year and down 10% from the previous quarter.
Gross margin was 85.0%, up 52.0 points from Q2 2025. Operating costs exceeded revenue by $197K, an operating margin of -3953.0%. Operating expenses fell 28% while revenue rose 55%. Net earnings were $150K. The effective tax rate was 0.0%. Non-operating items added $347K, 231% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$44K. Non-cash charges added back $2K of depreciation. Working capital and other items used $196K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 19, 2026 | $5K | +55% | n/m | $150K | −$44K |
| Q1 2026 | 10-Q | May 15, 2026 | $6K | — | n/m | −$111K | −$85K |
| Q4 2025 | 10-K | Apr 14, 2026 | $10K | — | n/m | −$823K | −$156K |
| Q3 2025 | 10-Q | Nov 14, 2025 | $5K | — | n/m | −$380K | −$151K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $3K | +377% | n/m | −$552K | −$111K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Bioadaptives
BioAdaptives, Inc., ("BioAdaptives," the "Company," "we" or "us") was incorporated in the State of Delaware on April 19, 2013, as APEX 8 Inc. From inception through October 21, 2013, the Company was in the developmental stage and conducted virtually no business operations, other than organizational activities and preparation of a registration statement on Form 10-12g (the "Registration Statement"), which was filed with the U.S. Securities and Exchange Commission on May 3, 2013. On June 11, 2013, the SEC staff informed the Company that it had no further comments.
In its own words, from its 10-K, filed Apr 14, 2026.
Bioadaptives against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +55% against the peers' median +10%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BDPT Bioadaptives | Q2 2026 | $5K | +55% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Bioadaptives 10-Q on SEC EDGAR · CIK 1575142 · Pharmaceutical Preparations
More on BDPT
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results